Biodexa Pharmaceuticals (BDRX) SC 13G Biodexa Pharmaceuticals / C/M CAPITAL PARTNERS ownership change

EXHIBIT 99.1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: February 18, 2025

C/M Capital Master Fund, LP

By: C/M Global GP, LLC, its General Partner

By:	/s/ Thomas Walsh
	Name: Thomas Walsh
	Title: Manager

C/M Capital Partners, LP

By:	/s/ Thomas Walsh
	Name: Thomas Walsh
	Title: Partner

/s/ Thomas Walsh

 Thomas Walsh

/s/ Jonathan Juchno

Jonathan Juchno